TRPV1


Also found in: Acronyms, Wikipedia.

TRPV1

A gene on chromosome 17p13.2 that encodes a protein which is a receptor for capsaicin and the structurally related vanilloids, and is a non-selective cation channel structurally related to the TRP family of ion channels. The receptor is also activated by high temperatures, suggesting that it functions as a transducer of noxious chemical and painful thermal stimuli in vivo.
Mentioned in ?
References in periodicals archive ?
The TRPV1 receptor is actively being researched to understand its properties, and in a recent German study it was found that the TRP channel polymorphisms contributed significantly to somatosensory abnormalities of neuropathic pain patients.
The scientists discovered that TRPV1, once activated by the EGFR, initiates a direct negative feedback on the EGFR, dampening the latter to reduce the risk of unwanted growth and intestinal tumor development.
University of California researcher Andrew Dillin said: "Ingestion of compounds that affect TRPV1 might help prevent metabolic decline with age.
Animals were pretreated [before exposure to either filtered air (FA) or wDE] with a TRPA1 antagonist (HC030031), a general TRP antagonist [ruthenium red (RR)i, of a TRPV1 antagonist (SB366791).
If sensory nerves contain pain receptors like TRPA1 and TRPV1, and itch receptors like MrgprA3 and MrgprC11, how does the cell distinguish between itch and pain?
Capsaicin binds to the TRPV1 channel (transient receptor potential channel A1 or vanilloid receptor 1) (Fig.
Under the terms of the Agreement, Wyeth has obtained an exclusive worldwide license to develop, manufacture, use and sell pharmaceutical products containing Mochida's TRPV1 antagonists.
Coronal pulps were removed and processed for indirect immunofluorescence using antibodies raised against TRPV1 and either the general neuronal marker, protein gene-product 9.
Pipeline candidates fall under major therapeutic classes such as NSAIDs, opioid receptors, AMPA and kainate sub-type receptors, kappa opioid receptors, conopeptide analogs, TRPV1 antagonists, Imidazoline I2 binding receptors, platelet glycoprotein IIb/IIIa receptors, Mu-opioid receptors, and ligand activated therapy.
Sorrento is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain.
Univers Andr comd University of California researcher Andrew Dillin said: "Ingestion of compounds that affect TRPV1 might help prevent metabolic decline with age.